JPRN-UMIN000005697
Completed
未知
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma - Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Chiba University Hospital
- Enrollment
- 42
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with a history of malignancy. 2\) Corresponding to the sever heart disease. 3\) Active clinically\-serious infections. 4\) History of HIV infection. 5\) Hemodialysis. 6\) Clinical or radiological evidence of CNS metastases. 7\) Uncontrollable massive ascites, pleural effusion. 8\) Clinically\-significant gastrointestinal bleeding within 4 weeks prior to study entry. 9\) Severe allergy for fluoropyrimidines. 10\) HBV\-DNA positive and not being treated with nucleotide analogues. 11\) Anticoagulant therapy with warfarin potassium. 12\) During treatment with Tegafur gimeracil oteracil potassium, or within 7 days after discontinuation. 13\) Use Sho\-saiko\-to. 14\) Use oral phenytoin. 15\) Severe thyroid disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43
Active, not recruiting
Not Applicable
A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer - NDEUCTR2006-003752-38-ITOSPEDALE ONCOLOGICO DI BARI
Completed
Phase 1
Phase I study of a combination of capecitabine plus CPT-11 (CC therapy) in patients with metastatic colon cancer refractory to oxaliplatin containing chemotherapyColorectal cancerJPRN-UMIN000003176Osaka Medical Center for Cancer and Cardiovascular Diseases24
Completed
Phase 1
Capecitabine and erlotinib in advanced lung cancerISRCTN18199864Royal Marsden NHS Foundation Trust40
Active, not recruiting
Not Applicable
Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinomfortgeschrittenes kolorektalen Karzinom mit inoperablen MetastasenMedDRA version: 9.1Level: LLTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2007-000233-18-DEniversität zu Köln